Use of FDG-PET in testicular tumours

Clinical Oncology

Volumn 15, Issue 3, 2003, Pages 123-127

  Huddart, R A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EDITORIAL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DECAY; SENSITIVITY AND SPECIFICITY; TESTIS TUMOR;

EID: 0038745665     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2002.0161     Document Type: Editorial

References (22)

1. Nichols C. Testicular cancer. Curr Probl Cancer 1998;22:187-274.
2. Aass N, Fossa SD, Ous S, et al. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer? Br J Urol 1990;65:385-390.
3. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998;39:815-822.
4. Stephens A, Gonin R, Hutchins G, Einhorn L. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-1641.
5. Hain S, O'Doherty M, Timothy A, Leslie M, Harper P, Huddart R. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863-869.
6. Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications]. Prog Urol 2000;10:1190-1199.
7. Bokemeyer C, Kollmannsberger C, Oechsle K, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002;86:506-511.
8. Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002;68:157-163.
9. Sugawara Y, Zasadny K, Grossman H, Francis I, Clarke M, Wahl R. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999;211(1):249-256.
10. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997;33:829-835.
11. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457-3460.
12. Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002;89:549-556.
13. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose position emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-3744.
14. Nuutinen JM, Leskinen S, Elomaa I, et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997;33:1234-1241.
15. Hain S, O'Doherty M, Timothy A, Leslie M, Partridge S, Huddart R. Fluorodeoxyglucose (PET) in the initial staging of germ cell tumours. Eur J Nuclear Med 2000;27:590-594.
16. International Germ Cell Consensus Classification. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
17. Aass N, Hatun DE, Thoresen M, Fossa SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997;45:125-128.
18. Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900-904.
19. Lassen U, Daugaard G, Rorth M, Eigtved A, Hojgaard L, Finsen Ctr NUH, Rigshopitalet, Copenhagan, Denmark. Position Emission Tomography with 18 F-Fluoro-Deoxyglucose in Clinical Stage I Non-Seminomatous Germ Cell Tumors. Program/Proceedings ASCO 2000;19:340a.
20. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999;53:808-811.
21. Muller-Mattheis V, Reinhardt M, Gerharz CD, et al. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]. Urologe Ausgabe A 1998;37:609-620.
22. Wilson CB, Young HE, Ott RJ, et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med 1995;22:508-513.